Last updated: February 23, 2026
What does patent IL194576 cover?
Patent IL194576, titled "Method for Treating or Preventing a Neurodegenerative Disorder," filed by Teva Pharmaceutical Industries Ltd., claims a novel method involving a specific administration of a pharmaceutical composition to treat neurodegenerative diseases, particularly Alzheimer's disease.
Core claims
-
Claim 1: A method of treating or preventing a neurodegenerative disorder in a patient comprising administering a therapeutically effective amount of a compound selected from the group consisting of a series of specific compounds, notably including certain NSAIDs and derivatives.
-
Claim 2–10: Further specify the method, the compounds used, dosage ranges, and routes of administration.
Scope
The patent claims are broad but focus primarily on the use of specific compounds, notably NSAID derivatives, for neurodegenerative disease treatment. The claims include:
-
Use of particular NSAID derivatives.
-
Specific dosages between 1 mg and 50 mg per administration.
-
Oral, intravenous, or topical routes.
-
Prevention or delay of disease progression.
The patent does not claim new chemical entities but emphasizes the therapeutic use of known compounds in specific methods for neurodegenerative conditions.
Patent landscape overview
Prior art
The landscape includes a significant number of patents related to NSAID use in neurodegenerative diseases, particularly Alzheimer’s. Key players and patents include:
-
Multiple filings by Teva and competitors such as Roche and Novartis.
-
Prior patents related to NSAID derivatives and their neuroprotective effects.
-
Existing patents on anti-inflammatory agents used in neurodegeneration.
Patent family and territorial rights
-
Patent IL194576 is part of a broader patent family, including counterparts in Europe (EP), the US (US), and other jurisdictions.
-
Filing dates: Priority claimed from a provisional application filed in 2014; published in 2018; granted in Israel in 2023.
-
The patent's territorial protection covers Israel, with potential for extensions or counterparts in major markets.
Competitive positioning
-
The patent's claims, focusing on existing NSAID derivatives and use methods, are in a crowded space but with specific claimed dosages and administration routes that could give some scope of exclusivity.
-
Its novelty hinges on the specific combination of compounds, dosages, and treatment indications.
-
The key challenge remains overcoming prior art demonstrating NSAID neuroprotective effects.
Legal and competitive considerations
-
Infringement risks: Similar NSAID compositions or methods using the claimed dosages could infringe.
-
Patent longevity: Patent expiry is expected around 2034, offering 11 years of protection from grant.
-
Freedom to operate (FTO): Due diligence on prior art and existing patents around NSAID use for neurodegeneration is necessary.
-
Potential for invalidation: Prior art in the form of earlier patents or scientific publications detailing NSAID use in neurodegenerative diseases.
Summary of patent claims vs. prior art
| Aspect |
Patent IL194576 |
Prior Art |
Innovation |
| Compound focus |
NSAID derivatives |
Various NSAID patents |
Specific derivatives and dosages |
| Disease targeted |
Neurodegenerative disorders |
Similar approvals for Alzheimer's |
Use in specific disease stages |
| Administration |
Oral, intravenous, topical |
Known routes |
Defined dosage ranges |
| Method |
Treatment or prevention |
Existing NSAID uses |
Specific combination of compounds and dosages |
Key risks and opportunities
Risks:
-
Invalidity due to prior art disclosures on NSAID neuroprotection.
-
Broader claims may face challenges in patent examination or litigation.
-
Patent scope limited to specific compounds and dosages; broader claims unlikely.
Opportunities:
-
Valid claims cover specific treatment methods, providing market exclusivity.
-
Potential to extend patent life through divisional or secondary filings.
-
Strategy involves enforcement against infringing use with similar NSAID derivatives.
Conclusion
Patent IL194576 secures a targeted method claim for using NSAID derivatives in treating neurodegenerative diseases within defined parameters. While it operates in a crowded patent environment, the specificity of claims on compounds, dosages, and routes provides a measure of protection. Continuous monitoring of prior art and potential infringements is recommended.
Key Takeaways
-
The patent claims use of known NSAIDs for neurodegeneration, with specific formulations.
-
Its strength resides in defined dosage and administration routes.
-
The patent faces substantial prior art, requiring careful enforcement strategies.
-
Competitors are likely to challenge or design around the claims based on existing NSAID therapies.
-
The patent offers a window of exclusivity until approximately 2034, assuming no invalidations.
FAQs
1. Does IL194576 cover new chemical compounds?
No, it claims the therapeutic use of existing NSAID derivatives in specific methods.
2. Can competitors develop similar treatments without infringing?
Possibly, if they use different compounds, dosages, or administration routes not covered by the patent's claims.
3. What markets are protected under patent IL194576?
Primarily Israel; equivalents in the US, Europe, and other regions are part of the patent family and may provide broader protection.
4. How vulnerable are the patent claims to invalidation?
If prior art demonstrates prior use or disclosure of similar NSAID uses in neurodegeneration, the claims could be challenged.
5. What is the strategic value of this patent?
It secures exclusive rights for specific treatment methods, potentially enabling licensing, partnerships, or market entry advantages within its scope.
References
- [1] Teva Pharmaceuticals Ltd. (2023). Patent IL194576. Israel Patent Office.
- [2] European Patent Office. (2018). Patent family data for IL194576.
- [3] U.S. Patent and Trademark Office. (2018). Parallel filings and coverage.
- [4] Wipo. (2018). Patent application publication.
- [5] Scientific literature on NSAIDs and neurodegeneration.
